挑战性血栓形成的双重直接口服抗凝剂治疗:一个案例系列
Nicholas L J Chornenki1, Heather McPhaden1, Erica A Peterson1
1Division of Hematology, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
Research and practice in thrombosis and haemostasis
|September 18, 2024
概括
双重直接口服抗凝剂 (DOAC) 治疗,结合XA因子抑制剂和达比加特兰,在治疗不耐药血栓瘤病例方面表现有前途. 这种方法可以防止没有出血的复发事件,这表明了难以治疗的血栓形成的潜在策略.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉血栓塞栓症 (VTE) 用抗凝药治疗可能会失败,导致渐进的血栓形成.
- 尽管服用抗凝血药物,但危及生命的血栓形成需要新的管理策略.
研究的目的:
- 为了评估双重直接口服抗凝剂 (DOAC) 治疗耐火性血栓的疗效和安全性.
- 评估在具有挑战性血栓形成的患者中使用XA因子抑制剂和达比加特兰的组合.
主要方法:
- 对接受同时服用达比加特兰和口服FXa抑制剂的患者的回顾性图表审查.
- 纳入标准:18岁以上的耐火性血栓瘤患者.
主要成果:
- 八名耐火性血栓瘤患者接受了双DOAC治疗.
- 在双DOAC治疗期间,没有复发的深静脉血栓,肺栓塞或出血事件发生.
- 大多数患者在治疗后成功过渡到单个口服FXa抑制剂.
结论:
- 双DOAC疗法为管理对标准抗凝药耐药的复杂血栓症病例提供了潜在的策略.
- 需要进一步的研究来证实这些发现,并探索双DOAC治疗的更广泛的应用.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496


